Overview

Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI

Status:
Enrolling by invitation
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Cerebrovascular disease is a major source of neural injury and there is an urgent need for comprehensive evaluation of these patients. High-resolution MRI (HR-MRI) allows direct visualization of intracranial vessel wall pathology in the setting of acute ischemic stroke and intracranial aneurysm (intracranial aneurysm rupture.Vessel wall enhancement on HR-MRI results from inflammation and has considerable potential as a marker of future stroke risk or aneurysm rupture. We will use our HR-MRIvwMRI protocol and other techniques of measuring plaque and aneurysms vulnerability, including laboratory markers of abnormal inflammation and oxidization, which have been shown to correlate with vulnerable carotid atherosclerosis and intracranial aneurysms, but have not been studied in symptomatic ICAS or IA.The unmet need is a study validating HR-MRI reliability and the association of vessel-wall enhancement with both symptomatic and pro-inflammatory status in patients with cerebrovascular disease.
Phase:
Phase 1
Details
Lead Sponsor:
University of Utah
Collaborator:
AMAG Pharmaceuticals, Inc.
Treatments:
Ferrosoferric Oxide